The association of smoking status with SARS‐CoV‐2 infection, hospitalization and mortality from COVID‐19: a living rapid evidence review with Bayesian meta …

D Simons, L Shahab, J Brown, O Perski - Addiction, 2021 - Wiley Online Library
Aims To estimate the association of smoking status with rates of (i) infection,(ii)
hospitalization,(iii) disease severity and (iv) mortality from SARS‐CoV‐2/COVID‐19 disease …

[HTML][HTML] The immune response to SARS-CoV-2 and COVID-19 immunopathology–Current perspectives

JL Boechat, I Chora, A Morais, L Delgado - Pulmonology, 2021 - Elsevier
SARS-CoV-2 is a new beta coronavirus, similar to SARS-CoV-1, that emerged at the end of
2019 in the Hubei province of China. It is responsible for coronavirus disease 2019 (COVID …

Hyperinflammatory immune response and COVID-19: a double edged sword

LY Tan, TV Komarasamy… - Frontiers in …, 2021 - frontiersin.org
The coronavirus disease-19 (COVID-19) elicited by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has caused devastating health, economic and social impact …

Neutralizing antibodies for the prevention and treatment of COVID-19

L Du, Y Yang, X Zhang - Cellular & molecular immunology, 2021 - nature.com
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) initiates the infection
process by binding to the viral cellular receptor angiotensin-converting enzyme 2 through …

COVID-19 and the role of cytokines in this disease

A Hasanvand - Inflammopharmacology, 2022 - Springer
Studies have shown that SARS-CoV-2 has the ability to activate and mature proinflammatory
cytokines in the body. Cytokine markers are a group of polypeptide signalling molecules that …

[HTML][HTML] Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review

A Cortegiani, M Ippolito, M Greco, V Granone, A Protti… - Pulmonology, 2021 - Elsevier
Background Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of
severe COVID-19. The aim of this systematic review was to describe the rationale for the use …

The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication

Q Ning, D Wu, X Wang, D Xi, T Chen, G Chen… - Signal transduction and …, 2022 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) is a highly transmissible disease
caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that poses a …

Impacto del confinamiento por COVID-19 en la calidad de vida y salud mental

CL Ballena, L Cabrejos, Y Davila… - Revista del Cuerpo …, 2021 - scielo.org.pe
Introducción: La pandemia por SARS-Cov-2 ha tenido un impacto negativo en múltiples
aspectos de la vida humana, tanto en lo físico, psicológico, económico, social y cultural. Las …

Immune therapy, or antiviral therapy, or both for COVID-19: a systematic review

F Cantini, D Goletti, L Petrone, S Najafi Fard, L Niccoli… - Drugs, 2020 - Springer
Background Based on current evidence, recent guidelines of the National Institute of Health,
USA indicated the use of remdesivir and dexamethasone for the treatment of COVID-19 …

[HTML][HTML] The role of Interleukin 6 inhibitors in therapy of severe COVID-19

E Nasonov, M Samsonov - Biomedicine & Pharmacotherapy, 2020 - Elsevier
Cytokine storm syndrome (CSS) is a severe complication of inflammatory immune diseases
or treatment of malignancies; it may also appear during the progression of COVID-19. CSS …